Outcome of the Board Meeting held on 11th March, 2026 pursuant to Regulation 30 the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
CRAFTSMAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Craftsman Automation's board, at its meeting on 11th March 2026, approved a phased internal restructuring of its Aluminium Products business. In the first phase, the boards of two material wholly owned subsidiaries — DR Axion India Limited (DRA) and Sunbeam Lightweighting Solutions Limited — approved a draft Composite Scheme of Arrangement. The scheme involves: (a) merging two step-down wholly owned subsidiaries (Suprash Developers and Srikara Technologies, which hold land parcels) into DRA; (b) then merging DRA into Sunbeam; and (c) reorganising Sunbeam's equity share capital. Key financials as of 31 March 2025: DRA had turnover of ₹1,298.52 crore and net worth of ₹511.34 crore, while Sunbeam had turnover of ₹1,237.46 crore and net worth of ₹107.43 crore. The rationale is to consolidate the fragmented Aluminium operations and land assets under a single focused entity with a stronger balance sheet, streamlined structure, and better ability to capitalise on expected industry growth. The exchange ratio for the DRA–Sunbeam merger is 1 Sunbeam share (face value ₹1 at ₹9 premium) for every 1 DRA share (face value ₹10). Craftsman Automation itself is not a party to the scheme and its shareholding pattern remains unchanged. The scheme is subject to NCLT, shareholder, creditor, and other regulatory approvals.
This is an internal restructuring among wholly owned subsidiaries and does not directly affect Craftsman Automation's shareholding or capital structure. However, it consolidates the Aluminium business into one entity, which could improve operational efficiency and long-term growth prospects, though the actual benefits will depend on successful execution and regulatory approvals.